Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?
- PMID: 35833128
- PMCID: PMC9271782
- DOI: 10.3389/fimmu.2022.915580
Myocarditis Following COVID-19 Vaccine Use: Can It Play a Role for Conditioning Immunization Schedules?
Abstract
Myocarditis (MYO) is a relatively uncommon inflammatory disease that involves the heart muscle. It can be a very severe disease as it can lead to the development of acute or chronic heart failure and, in a not marginal number of cases, to death. Most of the cases are diagnosed in healthy people younger than 30 years of age. Moreover, males are affected about twice as much as females. Viruses are among the most common causes of MYO, but how viral infection can lead to MYO development is not precisely defined. After COVID-19 pandemic declaration, incidence rate of MYO has significantly increased worldwide because of the SARS-CoV-2 infection. After the introduction of anti-COVID-19 vaccines, reports of post-immunization MYO have emerged, suggesting that a further cause of MYO together with the SARS-CoV-2 infection could increase the risk of heart damage during pandemic. Main aim of this study is to discuss present knowledge regarding etiopathogenesis and clinical findings of MYO associated with COVID-19 vaccine administration and whether the risk of this adverse events can modify the initially suggested recommendation for the use of COVID-19 vaccines in pediatric age. Literature analysis showed that MYO is an adverse event that can follow the COVID-19 immunization with mRNA vaccines in few persons, particularly young adults, adolescents, and older children. It is generally a mild disease that should not modify the present recommendations for immunization with the authorized COVID-19 mRNA vaccines. Despite this, further studies are needed to evaluate presently undefined aspects of MYO development after COVID-19 vaccine administration and reduce the risk of development of this kind of vaccine complication. Together with a better definition of the true incidence of MYO and the exact role of the various factors in conditioning incidence variations, it is essential to establish long-term evolution of acute COVID-19 related MYO.
Keywords: COVID-19; COVID-19 vaccine; heart; myocarditis; vaccine safety.
Copyright © 2022 Esposito, Caminiti, Giordano, Argentiero, Ramundo and Principi.
Conflict of interest statement
SE: Speaker’s fees from GSK, Pfizer, Novartis, Sanofi Pasteur, MSD and Vifor in the past three years. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Similar articles
-
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34237049 Free PMC article.
-
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833. JAMA Cardiol. 2021. PMID: 34185045 Free PMC article.
-
Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis.BMJ Open. 2023 Jun 20;13(6):e065687. doi: 10.1136/bmjopen-2022-065687. BMJ Open. 2023. PMID: 37339840 Free PMC article.
-
Public Interest in Myocarditis during the SARS-CoV-2 Pandemic.Disaster Med Public Health Prep. 2023 Mar 13;17:e349. doi: 10.1017/dmp.2022.307. Disaster Med Public Health Prep. 2023. PMID: 36912741
-
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445. BMJ. 2022. PMID: 35830976 Free PMC article. Review.
Cited by
-
SARS-CoV2 mRNA vaccine intravenous administration induces myocarditis in chronic inflammation.PLoS One. 2024 Oct 10;19(10):e0311726. doi: 10.1371/journal.pone.0311726. eCollection 2024. PLoS One. 2024. PMID: 39388490 Free PMC article.
-
Myocarditis and Pericarditis Post-mRNA COVID-19 Vaccination: Insights from a Pharmacovigilance Perspective.J Clin Med. 2023 Jul 28;12(15):4971. doi: 10.3390/jcm12154971. J Clin Med. 2023. PMID: 37568373 Free PMC article.
-
Positive Predictive Value of ICD-10-CM Codes for Myocarditis in Claims Data: A Multi-Institutional Study in Taiwan.Clin Epidemiol. 2023 Apr 6;15:459-468. doi: 10.2147/CLEP.S405660. eCollection 2023. Clin Epidemiol. 2023. PMID: 37057126 Free PMC article.
-
Cardiovascular Sequelae of the COVID-19 Vaccines.Cureus. 2025 Apr 10;17(4):e82041. doi: 10.7759/cureus.82041. eCollection 2025 Apr. Cureus. 2025. PMID: 40351947 Free PMC article. Review.
-
COVID-19 mRNA Vaccines: The Molecular Basis of Some Adverse Events.Vaccines (Basel). 2023 Mar 28;11(4):747. doi: 10.3390/vaccines11040747. Vaccines (Basel). 2023. PMID: 37112659 Free PMC article. Review.
References
-
- Bowles NE, Ni J, Kearney DL, Pauschinger M, Schultheiss HP, McCarthy R, et al. . Detection of Viruses in Myocardial Tissues by Polymerase Chain Reaction: Evidence of Adenovirus as a Common Cause of Myocarditis in Children and Adults. J Am Coll Cardiol (2003) 42:466–72. doi: 10.1016/S0735-1097(03)00648-X - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous